Abstract
Cardiovascular disease (CVD) prevalence in Kenya is rising. Overweight, pre-hypertension and physical inactivity in younger ages is contributory. These risk factors are inadequately documented among Kenyan children and adolescents, hampering CVD prevention.
This cross-sectional study randomly sampled 384 school children and adolescents. After obtaining assent and consent, global physical activity (PA) questionnaire was used to assess PA. Body mass index (BMI), Waist-Hip Ratio (WHR) and Waist-Height Ratio (WHtR) were determined. Blood pressure (BP) was also measured.
Participants were 14.6±2.7 years, and 62.6% were female. Overall BMI was 19.8±3.9 kg/m2 with 8% having ≥25.0 kg/m2, 87% of whom were in secondary schools. Using SBP, 27.9% were at risk of CVD. For age ≥13 years old, males and females proportions were 42.5% and 20% respectively while that for <13 years old, it was 26.5% and 27% respectively. For DBP, 12.8% had elevated- to-hypertensive BP. For ages ≥ 13 years old, this was 13.2% and 8.3% for males and females respectively and for the <13 years old, the respective percentages were 11.8 and 25.4. Combining SBP and DBP, 8.1% of participants, mostly males, had elevated-to-hypertensive BP. Thirty-one percent of boys and 15.6% of girls were at CVD risk using respective WHR cutoffs of 0.90 and 0.85 (males, 0.93±0.02; females, 0.89±0.03). For WHtR, 39.6% of boys had values >0.463 cut-off (0.493±0.02), with 52.6% in secondary schools against 32.4% for girls having >0.469 cut-off (0.517±0.05), 69.7% being in secondary schools. Overall, 45% of participants were sports-inactive and 77.2% did minimal PA.
Among school-going children and adolescents in Eldoret, Kenya, prevalence of CVD risk-factors was high especially among boys and in high schools. Large proportions had elevated BP, BMI, WHR and WHtR, and, further, were sedentary, posing high CVD risk. Lifestyle interventions to mitigate this public health concern among children and adolescent are urgently needed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
KM was supported by the Consortium for Advanced Research Training in Africa (CARTA). CARTA is jointly led by the African Population and Health Research Center and the University of the Witwatersrand and funded by the Carnegie Corporation of New York (Grant No. G-19-57145), Sida (Grant No:54100113), Uppsala Monitoring Center, Norwegian Agency for Development Cooperation (Norad), and by the Wellcome Trust [reference no. 107768/Z/15/Z] and the UK Foreign, Commonwealth & Development Office, with support from the Developing Excellence in Leadership, Training and Science in Africa (DELTAS Africa) programme. The statements made and views expressed are solely the responsibility of the Fellow.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Moi Teaching and Referral Hospital / Moi University Institutional Research Ethics Committee (MTRH/MU IREC) (approval number FAN: 0004291) and obtained research permit from the National Commission for Science, Technology and Innovation (NACOSTI) permit Ref number 839919.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
data availed as supporting information file
